
Cytomos appoints life sciences executive to board
pharmafile | September 2, 2026 | Appointment | | Alex Jones, Cytomos, non-executive director
Edinburgh-based biotechnology company Cytomos has appointed life sciences executive Dr Alex Jones as a non-executive director as it moves to accelerate the commercialisation of its cell analysis technology.
Jones, who is CEO of Cellply and previously led Cellular Highways, brings experience in life science tools and cell and gene therapy, including building and scaling technology companies, raising growth capital and delivering exits.
He joins Cytomos’ three-member board, chaired by Executive Chair Alan Raymond, and will support the company’s commercial drive around its AuraCyt cell analytic intelligence platform and Celledonia benchtop technology.
Cytomos says its AuraCyt platform is designed to address the complexity and cost of developing and manufacturing cell-derived medicines by enabling real-time monitoring and prediction of cell parameters. The company says the technology could allow biopharma companies to bring therapies to market up to six months faster while reducing development costs by enabling critical decisions to be made earlier.
The company has already engaged with several strategic partners seeking to integrate its technology into existing workflows, supported by a team of scientists and data analysts.
Raymond said Jones’ experience in building and scaling life sciences companies would be particularly valuable as Cytomos enters a “critical commercial growth phase”.
Jones said the predictive capability of AuraCyt has the potential to accelerate therapy development while significantly reducing costs.





